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ABSTRACT: The third and most recently identified Parkinson’s disease-linked variant of the neuronal protein
R-synuclein to be identified (E46K) results in widespread brain pathology and early onset Parkinson
symptoms (Zarranz et al. (2004) Ann. Neurol. 55, 164-173). Herein, we present biochemical and
biophysical characterization of E46K R-synuclein in various states of aggregation. Circular dichroism
and nuclear magnetic resonance spectroscopy illustrate that the E46K mutation results in subtle changes
in the conformation of the monomeric protein both free in solution and in the presence of SDS micelles.
However, it does not alter the overall helical propensity of the protein in the presence of phospholipids.
E46K R-synuclein formed insoluble fibrils in Vitro more rapidly than the wild type protein, and electron
microscopy revealed that E46K R-synuclein fibrils possess a typical amyloid ultrastructure. E46K
R-synuclein protofibrils, soluble aggregates that form during the transition from the monomeric form to
the fibrillar form of R-synuclein, were characterized by electron microscopy and gel filtration and were
found to include annular species. The unique ability of a subfraction of E46K and wild type R-synuclein
protofibrils containing porelike species to permeabilize lipid vesicles was demonstrated in Vitro using a
real-time chromatographic method. In contrast to simplistic expectations, the total amount of protofibrils
and the amount of permeabilizing activity per mole protein in the protofibril fraction were reduced by the
E46K mutation. These results suggest that if the porelike activity of R-synuclein is important for
neurotoxicity, there must be factors in the neuronal cytoplasm that reverse the trends in the intrinsic
properties of E46K versus WT R-synuclein that are observed in Vitro.
Parkinson’s disease (PD1) is a progressive neurodegen-
erative disorder characterized by resting tremor, bradykinesia,
rigidity, and postural instability due to the selective loss of
dopaminergic neurons within the substantia nigra (2, 3).
While nearly all cases of PD are idiopathic, rare forms of
autosomal dominant PD have been linked to the point
mutations A53T (4), A30P (5), and E46K (1) in R-synuclein,
a presynaptic protein believed to be involved in synaptic
vesicle trafficking (6, 7). Linkage between idiopathic PD and
R-synuclein is suggested by the discovery that Lewy bodies
(LB), intraneuronal cytoplasmic inclusions in the substantia
nigra that are the pathological hallmark of PD, are composed
primarily of fibrillar R-synuclein (8).
Monomeric R-synuclein is natively unfolded in solution
(9), but assumes â-sheet character as it aggregates through
a series of intermediate, metastable oligomeric states (termed
protofibrils) to a stable fibrillar conformation (10). In Vitro
studies have shown that both the A53T and A30P mutations
in R-synuclein alter the kinetics of fibrillization; the rate is
increased for the A53T variant and retarded by the A30P
substitution (11, 12). However, in both cases the rates of
formation of prefibrillar oligomeric species are increased in
comparison to wild type protein, suggesting a link between
these protofibrils and disease (10). Initial studies involving
E46K R-synuclein indicate that the mutation enhances the
formation of fibrillar species (13-15), but no examination
of the formation of soluble aggregates has been reported.
Electron microscopy (EM) studies reveal that preparations
of oligomeric R-synuclein contain annular species that form
as monomeric R-synuclein progressively assembles into
fibrils (16, 17). Indeed, R-synuclein protofibrils, comprising
either WT or the disease-associated variants, possess porelike
activity and permeabilize negatively charged phos-
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pholipid vesicles in Vitro (18, 19). This property is not
observed with monomeric or fibrillar R-synuclein. Studies
in ViVo support the theory that nonfibrillar aggregates of
R-synuclein are associated with neuronal pathology, as
R-synuclein-mediated toxicity in transgenic mice and Droso-
phila does not correlate with the appearance of fibrillar
inclusions (20-22).
The identification of E46K R-synuclein as the third
pathogenic variant of the protein not only reinforces the
strong connection between the protein and neurodegenera-
tion; it also presents an opportunity to evaluate and refine
current molecular models of R-synuclein-mediated cytotox-
icity. Previously, we proposed a model in which the
formation of oligomeric protofibrils is linked to PD pathology
(the toxic protofibril hypothesis) (23). Herein, we describe
the biochemical and biophysical properties of E46K R-sy-
nuclein, including structural characterization of the protein
in its free and membrane-associated states, the aggregation
dynamics of the variant in relation to wild type (WT)
R-synuclein, fibrillar and protofibrillar morphology, and the
vesicle permeabilization activity of protofibrillar species.
These results impact our current understanding of the toxic
protofibril hypothesis.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of R-Synuclein
Variants. E46K R-synuclein mutant constructs were gener-
ated using oligonucleotide site-directed mutagenesis of
previously generated wild type constructs (for NMR experi-
ments) or using the megaprimer PCR method (24, 25) (for
all other experiments), with the resulting PCR product ligated
into the pT7-7 Escherichia coli expression vector (26).
Isotopically labeled protein for NMR studies was expressed
and purified using established protocols (27), and all proteins
used in the other studies described were expressed as
previously described (28) and isolated by the procedure
below. Importantly, both protocols yield synuclein samples
that give rise to identical NMR spectra (27). Cell lysis
(Microfluidics Corporation M110-EHI) was followed by
ammonium sulfate precipitation (30% w/v solution), anion
exchangechromatography(AmershamBiosciencesQSepharose)
in 10 mM Tris-HCl/1 mM EDTA/pH 8.0, and cation
exchangechromatography(AmershamBiosciencesSSepharose)
in 10 mM sodium acetate/1 mM EDTA/pH 4.0. The final
homogeneity of each preparation was determined by densi-
tometric analysis of Coomassie-stained SDS-PAGE gel
scans (NIH Image 1.61/ppc program). Purified preparations
were lyophilized from ammonium bicarbonate buffer
(100 mM) (buffer exchange achieved by Amersham Bio-
sciences G25 chromatography) and stored at -20 °C until
use.
Size Exclusion Chromatography. Lyophilized samples of
several variants including WT, E46K, and A53T R-synuclein
were resuspended in 10 mM HEPES-NaOH/145 mM KCl/
pH 7.4 (HBS) to an approximate concentration of 200 íM.
Insoluble material was removed by 0.2 ím filtration (Mil-
lipore) prior to injection of each R-synuclein preparation onto
a 24 mL Superose 6 gel filtration column (Amersham
Biosciences) previously equilibrated in HBS. The eluate,
passed through the column at 0.5 mL/min, was monitored
with a Waters 996 PDA detector (Waters Corporation).
Retention times were determined using Waters Millennium
data processing software (Waters Corporation).
Circular Dichroism Spectroscopy (CD). WT and E46K
R-synuclein protein solutions (60 íM) were each prepared
in distilled water or distilled water containing various
concentrations of L-R-phosphatidyl-DL-glycerol (PG) vesicles
in 1 mM HEPES-NaOH/14.5 mM KCl/0.1 mM EDTA/pH
7.4. Far-UV CD spectra were obtained in a 0.1 cm cuvette
using an Aviv 62A DS spectropolarimeter at 25 °C.
Measurements were made at 1 nm intervals with 5-10 s
response times, and the final curves for each sample represent
the mean of three separate scans.
Nuclear Magnetic Resonance (NMR) Spectroscopy. Samples
for NMR experiments were made to 140 íM protein
concentration. For the free state, lyophilized protein was
dissolved in sample buffer (100 mM NaCl, 10 mM Na2HPO4,
pH 7.4 in 90%/10% H2O/D2O) followed by the removal of
any residual large-scale aggregates using Microcon YM-100
centrifugal filters (Millipore). Samples containing SDS
micelles were prepared by dissolving the protein in sample
buffer containing 40 mM SDS. All NMR experiments were
performed on a 600 MHz Varian INOVA spectrometer, at a
sample temperature of either 10 °C (free state) or 40 °C (SDS
micelles bound state). Spectra were recorded in succession
from matched wild type and E46K samples. Data were
processed with NMRPipe (29) and analyzed using NMR-
View (30). Spectra were referenced indirectly to DSS and
ammonia (31) using the known chemical shift of water.
Resonances for the mutant protein were assigned by inspec-
tion and comparison with the previously assigned spectra of
the wild type protein, and are therefore tentative in some
cases, though for many resonances the assignments could
be made confidently.
Preparation of R-Synuclein Solutions for Fibrillization
Studies. Lyophilized protein samples were dissolved in
10 mM Tris-HCl/150 mM NaCl/pH 7.4 with 0.02% sodium
azide (TBS/azide) to achieve an approximate concentration
of 4 mg/mL. Successive filtration through 0.2 ím filter units
(Millipore) and 100 kDa MWCO filter units (Millipore) was
performed to prepare homogeneous, monomeric protein
solutions. The total protein concentration of each filtrate
solution was determined by UV absorbance (280 nm), BCA
assay (Pierce), and/or quantitative amino acid analysis.
Samples were diluted to a total protein concentration of 70
íM in a total volume of 1.0 mL of TBS/azide in 1.5 mL
polypropylene centrifuge tubes. The samples were incubated
at 37 °C in a tissue culture roller drum (New Brunswick
Scientific Co., model TC-7) rotating at 43 rpm. Aliquots were
removed from the roller drum at 4 h intervals for time point
sampling.
ThioflaVin T Fluorescence Assay for Fibril Formation.
Aliquots of the R-synuclein incubations were assayed in
triplicate at a concentration of 5 íM by Thioflavin T (ThioT)
fluorescence as described previously (32).
Gel Filtration and UV Absorbance Measurements of
Fibrillization Samples. Relative monomer concentrations
within fibrillization time point samples were determined by
monitoring the UV absorption at 280 nm of the effluent from
a Shodex KW-G column (Showa Denko) as described
previously (28). Peak areas were integrated using Waters
Millennium Software (Waters Corp).
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Electron Microscopy. For protofibril morphology evalu-
ation, the oligomeric fraction of a protofibril-enriched
R-synuclein preparation was separated from the monomeric
fraction using a Superdex 200 gel filtration column (Amer-
sham Biosciences) run in HBS/EDTA, and pools were
concentrated using 10 kDa MWCO centrifuge filter units
(Millipore). For analysis of fibril morphology, insoluble
material generated during a typical fibrillization study (as
described above) was isolated by centrifugation at 12000g
for 5 min. Resulting pellets were resuspended in 150 íL of
10 mM Tris-HCl/pH 8.0. Each sample was coated neat on a
Formvar- and carbon-coated copper grid and washed with
two drops of distilled water and one drop of uranyl acetate
(6 mg/mL). The grids were then stained with uranyl acetate
(6 mg/mL) for 1 min. The samples were then studied in an
80 kV Jeol-1200EX electron microscope; protofibril samples
were examined at a magnification of 25000-30000 and
fibril samples at 10000-60000. The grids were thoroughly
examined, and representative samples of the structures
present in the sample were recorded on film.
Preparation of R-Synuclein Oligomeric Species. As previ-
ously reported, soluble aggregates of R-synuclein can be
isolated from a solution resulting from the resuspension of
lyophilized R-synuclein protein (16, 18). To achieve con-
sistently high and reproducible yields of these oligomeric
species, the following changes to the established protocol
were introduced. Lyophilized R-synuclein protein was re-
suspended in ammonium bicarbonate buffer (100 mM),
diluted in the same buffer to a set concentration (typically
200 íM), and then flash frozen in liquid nitrogen in a fully
upright position before relyophilization. This procedure
ensured that each preparation presented the same exposed
surface area during lyophilization in order to minimize
differences in the rate of sublimation between samples. The
dehydrated powder was resuspended to 400 íM final
concentration in 10 mM HEPES-NaOH/145 mM KCl/1 mM
EDTA/pH 7.4 (HBS/EDTA). Insoluble aggregates were
removed by 0.2 ím filtration, and preparations were stored
at 4 °C for no more than one week before analysis.
Synthetic Vesicle Permeabilization. Activity measurements
of R-synuclein protofibril fractions were obtained by an
online permeabilization method developed by Volles (33),
with minor modifications. In brief, PG vesicles loaded with
the calcium-sensitive fluorescent dye fura-2 were created as
described previously (19) and diluted to approximately
0.1 mg/mL (Note: the precise dilution of each vesicle
preparation was determined empirically so that each prepara-
tion yielded a baseline fluorescence of 500 RFU) in 10 mM
HEPES-NaOH/145 mM KCl/5 mM CaCl2/pH 7.4 (HBS/Ca).
Protofibril-enriched R-synuclein solutions were resolved
using a 24 mL Superose 6 column (Amersham Bioscience)
equilibrated in HBS (no calcium). The effluent from the
column (at a flow rate of 0.5 mL/min) was passed through
a spectrophotometer (Waters PDA 996) and then was
combined with the vesicle solution delivered by syringe
pump (at a flow rate of 0.1 mL/min). After 0.6 mL (1 min)
of tubing in which to interact, the protein/vesicle mixture
was passed through a scanning fluorescence detector (Waters
model 474) to measure the fluorescence increase at 500 nm
(334 nm excitation, 40 nm bandwidth) upon exposure of
fura-2 to Ca2+. Molar permeabilization activity of each
quaternary structural fraction was determined by integration
of the peak of 280 nm absorbance (22.5 min retention time)
and the peak of 500 nm fluorescence (23 min retention time)
(Waters Millenium software).
RESULTS
Monomeric E46K and WT R-Synuclein Share Similar, but
Not Identical, Physical Properties. The E46K variant of
R-synuclein displays gross solubility and electrostatic proper-
ties similar to those of WT R-synuclein, as identical
purification protocols are sufficient to achieve a similar purity
level and yield for each variant. SDS-PAGE analysis
indicates that, like WT R-synuclein (data not shown), the
E46K variant can be isolated to >95% homogeneity (Sup-
porting Information Figure 1). However, the retention time
of E46K R-synuclein upon size exclusion chromatography
(SEC) analysis is increased in comparison to that of WT;
this is contrasted by the highly similar retention times of
the WT protein and another pathogenic R-synuclein variant,
A53T (Figure 1A). When analysis of variance testing is
applied to the mean retention times of the three variants, a
significant difference is detected (F(2,40) ) 14.16, p )
2  10-5); Tukey’s HSD pairwise comparison procedure
indicates that the differences in retention time between WT
and E46K R-synuclein and A53T and E46K R-synuclein are
statistically significant. Monomeric R-synuclein is known to
elute from SEC at an apparent molecular weight much higher
than its sequence-defined mass of 14 460 kDa; this discrep-
ancy may reflect the effect on Stokes radius of the protein’s
extended random coil conformation (ref 9, Figure 1B). The
increased retention time of E46K may therefore indicate that
the variant exists in solution in a slightly more compact form
than the WT protein. Although it is possible that the
difference in net charge between WT and E46K R-synuclein
results in a nonspecific ion-exchange interaction with the
column matrix, the probability of such an effect is minimized
by the ionic strength of the mobile phase (which contains
145 mM KCl).
CD analysis indicates a similar random coil secondary
structure for both E46K and WT R-synuclein when free in
solution (Figure 1B). In the presence of acidic phospholipid
vesicles, both E46K and WT R-synuclein undergo a structural
transition to a primarily R-helical state, indicating that the
mutation does not disrupt this known property of R-synuclein
(27, 34). This conversion from random coil to R-helix occurs
in a manner dependent on lipid concentration, and no
evidence for a mutation-linked alteration of membrane
affinity was revealed by these experiments, as both WT and
E46K R-synuclein displayed highly similar concentration
dependencies (Supporting Information Figure 2).
E46K Mutation of R-Synuclein Results in Subtle Changes
in Protein Conformation. We further examined the confor-
mation of monomeric R-synuclein in solution using NMR
spectroscopy, as chemical shifts of nuclei are sensitive
probes of local structure and chemical shift changes are
highly sensitive indicators of structural alterations. The
proton-nitrogen correlation (HSQC) spectrum of E46K
mutant R-synuclein overlaid with that of the WT protein
(Figure 2A) shows that residues close to the mutation point
(Lys43-Val49) shift noticeably with respect to WT, as would
be expected from the local change caused by the replacement
of the glutamate side chain with a lysine, but that the
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remainder of the spectrum appears largely unperturbed. To
further quantitate the spectral changes, the differences in the
weighted average of the amide proton and nitrogen chemical
shifts between the WT and mutant protein were calculated
and are plotted in Figure 2B. The data indicate that there
are no significant chemical shift perturbations away from
the site of the mutation. There were also no significant
changes in relative peak heights between the WT and mutant
spectra (data not shown).
In the presence of SDS micelles, the N-terminal lipid-
binding domain of R-synuclein adopts a structure consisting
of two helical segments that has been extensively character-
ized using NMR for WT (27, 35-37) as well as the A30P
and A53T mutants (38, 39). A comparison of proton-
nitrogen correlation spectra of the E46K and wild type
proteins (Figure 3A) reveals that while many resonances in
the previously assigned (35) wild type spectrum precisely
overlap equivalent resonances in the spectrum of the mutant,
a significant number of resonances are shifted in the presence
of the mutation. The clearest shifts occur for residues near
the mutation site (for example G41, S42, T44, G51, V52,
T54, and A56), as expected, many of which lie in the linker
region between the two micelle-bound helices. It is not
possible, based on these spectra, to assess whether these
changes occur only as a consequence of the change in the
local chemical environment caused by the presence of the
mutation, or whether they also reflect local structural
changes. In addition to local changes, however, many
resonances originating far from the site of mutation also shift
noticeably, including A19, E20, T22, V26, and A27, which
are located in the first helix of the micelle-bound protein,
and V63, G68, A69, V74, and G84, which are located in
the second helix. These chemical shift changes are not large
enough to indicate whole-scale alteration of the secondary
structure of the protein (this would be expected to result in
shift changes of 1 ppm or greater), and it is thus likely that
the two helices of the micelle-bound protein remain intact.
Nevertheless, there is clearly some change that occurs in the
environment of both helices as a result of the mutation, which
itself falls in the linker region.
Because the mutation-induced chemical shift changes for
the SDS-bound state are more substantial and widespread
than those observed for the free state, some resonance
assignments could not be transferred in a straightforward
manner from the wild type to the mutant spectrum, and at
present no independent assignments are available for the
SDS-bound E46K mutant. Therefore, to quantitate the
chemical shift changes between the wild type and mutant
proteins, we used the following strategy. Each wild type
resonance assignment was transferred to the nearest reso-
nance in the mutant protein spectrum, unless that resonance
was already assigned to a different (nearer) resonance, in
which case the next nearest resonance was selected. This
strategy is not foolproof, as resonances may shift unpredict-
ably and can even, for example, trade places in principle.
Nevertheless, in general this strategy will underestimate the
magnitude of the actual chemical shift change experienced
by any given resonance. Thus, a plot of the weighted average
of the thus estimated amide proton and nitrogen chemical
shift changes between the WT and mutant spectra should
allow for a reliable assessment of which regions of the
protein are affected by the mutation. Such a plot, shown in
Figure 3B, confirms that significant chemical shift changes
take place at sites distant from the E46K mutation, with
effects ranging approximately from residues 20 to 74. This
can be contrasted with the situation in the free state
(Figure 2B), where only local changes are observed.
E46K R-Synuclein Forms Fibrils More Rapidly Than WT
R-Synuclein. The formation of insoluble amyloid fibrils from
monomeric R-synuclein solutions is a well-documented
phenomenon, and the propensity of a particular variant of
R-synuclein to form fibrils in Vitro may relate to the
appearance of fibrillar deposits in the human brain. To
measure the incorporation of monomeric R-synuclein into
fibrils, we exploited the binding affinity of the fluorescent
dye ThioT for amyloid fibrils, as well as the altered solubility
characteristics of R-synuclein upon conversion to the fibrillar
form. Solutions of WT, E46K, or a 1:1 mixture of both
R-synuclein variants display loss of soluble monomer and
appearance of ThioT-reactive species upon incubation with
FIGURE 1: (A) Overlaid chromatograms displaying absorbance at 280 nm of solutions of WT (filled diamonds), E46K (open circles), and
A53T (filled squares) monomeric R-synuclein eluted from a Superose 6 size exclusion column. (B) CD spectra of purified WT and E46K
R-synuclein, in the presence of various concentrations of lipids. In isolation, both WT (open triangles) and E46K (filled triangles) assume
a random coil confirmation (single minimum at 198 nm). In the presence of 2 mg/mL PG vesicles, both WT (open squares) and E46K
(filled squares) assume primarily R-helical secondary structure (two minima at 209 and 221 nm). Also shown are solutions of WT and
E46K R-synuclein in the presence of 0.5 mg/mL PG vesicles (open and filled circles, respectively) and 0.25 mg/mL PG vesicles (open and
filled diamonds, respectively).
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agitation for 16 h as fibrils form in a nucleation-dependent
manner (Figure 4). The E46K variant forms fibrils most
readily, with a lag time of approximately 8 h. A previous
report established that the rate of E46K R-synuclein fibril
formation is similar to that of the A53T variant (13). WT
R-synuclein is considerably slower to form fibrils, with a
lag time of approximately 12 h. A 1:1 mixture of WT and
E46K (representative of the heterozygous condition in
patients) is intermediate in fibrillization propensity. For each
sample, enhancement of ThioT fluorescence appears at time
points corresponding to the initial loss of monomer, indicat-
ing incorporation of monomeric R-synuclein into fibrils
(Figure 4 inset). The fibrils formed by E46K R-synuclein
during the assay were analyzed by EM, and are morphologi-
cally similar to WT R-synuclein fibrils (Figure 5). The mutant
and WT fibrils are each approximately 10 nm in width, are
unbranched and appear rigid, and tend to associate into paired
helical filaments. These properties are consistent with those
of fibrillar R-synuclein isolated from diseased human brain
as well as with the defining characteristics of the broad class
of amyloid proteins (32).
E46K and WT R-Synuclein Form Annular Protofibrils. In
addition to fibrils, R-synuclein aggregation results in a variety
of soluble oligomeric species that seem to serve as fibrilli-
zation intermediates, or protofibrils (10, 16). In order to
examine the effects of the E46K mutation on the formation
of protofibrils, R-synuclein aggregates generated via lyo-
philization were separated from the monomeric species and
concentrated to facilitate analysis of the structural composi-
tion of the mixture of oligomeric forms. Figure 6A illustrates
E46K R-synuclein aggregate composition, and highlights the
formation of small (10-15 nm), distinct, and regular
FIGURE 2: (A) Overlaid contour plots of the 1H-15N HSQC spectra of WT (black) and E46K (red) R-synuclein in the free state. Amino
acid residues that shift with respect to the wild type protein are labeled. Labels in red correspond to ( 9 amino acid residues from the
mutation point. Residues that are further away are in black. (B) Mean weighted 1H-15N chemical shift differences [calculated as [(¢ä1H)2
+ (¢ä15N)2/25]1/2/2 (58)] between WT and E46K R-synuclein in the free state.
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elements, many of which appear to be annular in nature. WT
R-synuclein also generates numerous annular aggregates of
similar conformation to the E46K species, with diameters
ranging from 11 to 17 nm (Figure 6B). The conformation
and size of the porelike oligomeric structures presented here
are consistent with previous reports of R-synuclein aggregate
formation (16, 40), and no significant difference in the
average outer diameter of WT and E46K R-synuclein annular
protofibrils was revealed upon examination of images from
several independent experiments (data not shown). It is
important to note that these images serve to establish the
structural properties of individual oligomeric species formed
from each R-synuclein variant, and do not illustrate a
quantitative difference in the prevalence of annular protofibrils
among the broad array of aggregate forms generated by each
variant. In fact, the apparent difference in the abundance of
larger soluble oligomeric species between E46K and WT
R-synuclein in Figure 6 was examined but not substantiated
by quantitative SEC analysis (data not shown).
Permeabilizing ActiVity Is Confined to a Specific Subset
of R-Synuclein Oligomeric Species. The ability of R-sy-
nuclein protofibrils to disrupt synthetic phospholipid vesicles
has been extensively characterized (18, 19) and suggests a
potential mechanism of direct R-synuclein-mediated cyto-
toxicity. The development of an online permeabilization
assay (33) has facilitated the comparison of the vesicle
permeabilizing activity of E46K and WT R-synuclein ag-
gregates by reducing the time delay between isolation and
activity measurement, and by eliminating the need for
separate purification, filtration, and concentration determi-
nation steps. Such processing steps can allow re-equilibration
of the protein mixture, thereby altering the distribution of
FIGURE 3: (A) Overlaid contour plots of the 1H-15N HSQC spectra of WT (black) and E46K (red) in the SDS micelle-bound state. Resonance
assignments of the wild type protein are denoted, and for resonances that shift in the mutant spectrum the location of the resonance used
to calculate the chemical shift difference upon mutation, as described in the text, is noted. (B) Mean weighted 1H-15N chemical shift
differences [[(¢ä1H)2 + (¢ä15N)2/25]1/2/2 (57)] between WT and E46K R-synuclein in the SDS-bound state, calculated as described in the
text.
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oligomeric species (data not shown). Molar activity measure-
ments can be obtained from a single SEC eluate flow path
by determining the protein abundance at a given retention
time and the corresponding peak of vesicle permeabilization
(Figure 7). In addition, the simultaneous monitoring of the
protein quaternary structure distribution and permeabilizing
activity of R-synuclein preparations reveals information about
the nature of the active species. Figure 7 (blue trace)
illustrates the separation achieved by the Superose 6 SEC
column. The sharp peak at 15 min (termed Void) occurs at
the void volume of the column, and contains soluble
aggregates of >40 000 kDa molecular mass. The broad peak
at 22.5 min (termed Protofibril) contains smaller soluble
aggregates, including annular protofibrils (Supporting Infor-
mation Figure 3). The peak at 30 min (termed Dimer) is
composed of the dimeric form of R-synuclein, and the large
peak at 33 min (termed Monomer) contains the monomeric
form. When the protein within each of these peaks interacts
with vesicles containing the calcium-sensitive fluorescent dye
fura-2, a fluorescence signal is monitored to detect exposure
of the vesicle interior to the calcium-containing mobile phase
(Figure 7, red trace). To compare the activity levels of the
different aggregate forms of R-synuclein, molar activity
values were calculated as discussed above. The Void peak
elicits a slight fluorescence increase; the specific activity of
this subset of R-synuclein aggregates accounts for 2% of
the total activity of the heterogeneous R-synuclein prepara-
tion. This indicates that larger aggregation states of R-sy-
nuclein do not possess significant permeabilizing activity,
confirming earlier observations (18) and supporting the view
that a small oligomeric species contributes to the cellular
toxicity associated with PD (23). Monomeric R-synuclein
results in only 0.05% of the total membrane permeabilization
activity, and this value may be overestimated due to light
scattering caused by the high concentration of protein in the
fluorescence flow cell. The inability of monomeric R-sy-
nuclein to permeabilize vesicles has been demonstrated
previously (19) and suggests that R-synuclein must self-
associate in order to disrupt membranes. The relatively high
molar activity level of dimeric R-synuclein (1% of total
activity, 20-fold more active than Monomer) is unexpected
and merits further investigation. The predominant peak of
fluorescence is elicited by the Protofibril fraction; the specific
activity of this class of R-synuclein aggregates represents
97% of the total activity measured. The results of this
analysis indicate that the permeabilizing activity associated
with aggregated R-synuclein is confined nearly exclusively
to a subfraction of these aggregates that contains annular
species.
E46K R-Synuclein Protofibrils Permeabilize Synthetic
Vesicles, but Display Reduced ActiVity. The analysis depicted
in Figure 7 was employed to compare the relative vesicle
permeabilization activities of protofibrillar WT and E46K
R-synuclein. The permeabilizing activity of the protofibril
fraction from each variant was determined over a range of
protein concentrations, and the analysis was repeated with
several protein and PG vesicle preparations. Figure 8A
presents the cumulative data, and indicates that although
soluble oligomeric E46K R-synuclein permeabilizes phos-
pholipid vesicles, it does so at a lower activity level than
that of the WT protein. The activity of each variant is dose-
dependent and saturates at a roughly similar protein con-
centration. Each variant displays a distinct peak permeabi-
lization level, which indicates that the availability of intact
vesicles is not a general limitation of the assay. It is possible
that the saturability of the activity is the result of protofibril
self-association at higher concentrations. Figure 8B presents
the average molar activity values (permeabilization activity
per mole of total protein within the Protofibril peak) derived
from E46K or WT R-synuclein samples with relative
protofibril concentration values <20 (the presaturation
range), and confirms that the difference in activity between
WT and E46K R-synuclein soluble oligomeric species is
significant (p < 0.001 in an unpaired Student’s t test).
Protofibrils generated from an equimolar mixture of WT and
E46K monomeric protein display an average molar activity
intermediate to each pure solution, indicating that the mixture
results in no apparent synergistic effects. It is important to
note that this analysis is unable to distinguish between a
difference in individual mutant and WT protofibrils (the
mutation modifies each “pore”) and variation in the popula-
tion of oligomeric species generated (the mutation alters the
proportion of “pores” within the oligomeric mixture). Further
separation of oligomeric species would be required to
discriminate between these alternatives. Figure 8C illustrates
the significantly greater average yield of protofibrils gener-
ated in Vitro from WT R-synuclein as compared with the
E46K variant. Given the increased propensity of the E46K
variant to form fibrils, it is possible that a greater proportion
of the oligomeric material formed from this variant is of a
higher order than that formed by WT R-synuclein and is
removed during processing of the protofibril-enriched prepa-
rations due to a decrease in solubility and/or increased
retention during 0.2 ím filtration.
DISCUSSION
Compelling evidence links R-synuclein to the pathogenic
process that underlies PD. Aggregation of the protein appears
to play a central role in the disease, as indicated in part by
FIGURE 4: Fibrillization kinetics of pure samples of WT R-sy-
nuclein, E46K R-synuclein, and an equimolar mixture of both. All
samples were examined at 70 íM total protein concentration, with
43 rpm rolling agitation. WT, black diamonds; E46K, blue triangles;
WT:E46K (1:1), red circles. Inset graph displays ThioT reactivity
at early time points, confirming that fibrils form as monomeric
R-synuclein is removed from the solution. Data presented are
representative of three independent experiments (see also Supporting
Information Figure 4). Error bars represent plus or minus one
standard error of triplicate samples.
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the appearance of R-synuclein fibrils in Lewy bodies within
the human midbrain (8), the development of R-synuclein
inclusions in various animal models of PD (41-44), and the
apparent conversion of R-synuclein from a neuroprotective
agent at low concentrations to a neurotoxic agent at high
concentrations (7, 45). The contribution of a loss of normal
R-synuclein function to the disease phenotype is unclear.
Although evaluation of R-synuclein knock-out mice revealed
only minor neurotransmission deficits (46), a recent study
has demonstrated that R-synuclein functions in a redundant
manner with CspR, a presynaptic protein involved in SNARE
protein recycling (7). Loss of normal levels of soluble and
fully functional R-synuclein may expose the cell to increased
susceptibility to stress, and therefore the effect of sequence
modification on the soluble monomeric form of R-synuclein
is important to consider in addition to effects of mutation
on the aggregation of the protein.
Insight into the molecular mechanism by which R-sy-
nuclein aggregation may mediate neurotoxicity has been
gleaned from biophysical and biochemical characterization
of WT R-synuclein and the familial PD (FPD) R-synuclein
variants A53T and A30P. Accelerated fibrillization rate is
not a shared property of the A53T and A30P R-synuclein
variants, suggesting that an increase in fibrillization rate is
not required for an increase in toxicity (10). However, the
formation of intermediate aggregates (protofibrils) is en-
hanced by both mutations in comparison to the WT protein
(10). Although the existence of fibrillar LBs serves as the
FIGURE 5: Electron micrographs illustrating the similar ultrastructural characteristics of WT and E46K R-synuclein fibrils formed in Vitro.
(A) E46K and (B) WT R-synuclein fibrils recorded at 20000. Inset images at 60000 display the morphology of single fibrils.
FIGURE 6: Comparison of the conformation of R-synuclein oligomeric species by electron microscopy. (A) E46K and (B) WT R-synuclein
soluble oligomeric fractions examined at 25000 and 30000, respectively (please note that the magnification levels have been digitally
normalized to facilitate comparison of the images). Magnified region illustrates the appearance of annular structures within the solution
(arrows).
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hallmark diagnostic criterion for PD (47), isolated R-sy-
nuclein fibrils have proven to be relatively inert in vesicle
permeabilization assays (18). In contrast, protofibrils com-
prising R-synuclein demonstrate clear permeabilization activ-
ity; the FPD variants possess elevated specific permeabilizing
activity compared to the WT protein (19). The existence of
porelike elements within the array of soluble aggregates
formed by R-synuclein complements this functional data (16,
17, 40); based on these findings, the protofibril hypothesis
for R-synuclein-mediated neurodegeneration in PD was
proposed (23). The model predicts that a soluble, porelike
intermediate to R-synuclein fibril formation contributes to
cellular toxicity, and that the relative activity of the protofibrils
formed from a particular variant of R-synuclein correlates
to the relative level of toxicity created in the cell. Recent
studies have supported this theory by demonstrating that a
soluble oligomeric form of R-synuclein is toxic in cell culture
and animal models (21, 48-50).
The dynamics of E46K aggregation impact the current
understanding of the role of R-synuclein in PD pathogenesis.
Recent articles have reported that E46K R-synuclein exhibits
an increased rate of fibrillization, similar to that of the A53T
variant (13, 14). Our results confirm this finding, but extend
the analysis of E46K R-synuclein self-association to oligo-
meric structures that we believe have a greater predictive
value in terms of potential cellular toxicity. Two points
uncovered in this report provide further evidence in favor
of the protofibril hypothesis. First, the E46K R-synuclein
variant generates porelike soluble aggregates and displays
permeabilizing activity when in oligomeric form. These
annular oligomeric species are similar in size and morphol-
ogy to annular species isolated from A53T and A30P
R-synuclein as well as pathogenic Aâ variants (16, 40). The
conservation of these properties among neuropathic proteins
reinforces the robust nature of the phenomenon, and suggests
a link between these species and neurodegeneration. Second,
vesicle-permeabilizing activity has been exclusively at-
tributed to a subfraction of oligomeric R-synuclein that
contains annular structures. This supports the view that
R-synuclein can form a distinct oligomeric species that is
intrinsically disruptive to membranes; the SEC-based pro-
cedure presented here may facilitate the further isolation of
protofibril activity as higher-resolution separation methods
are developed.
Although E46K R-synuclein retains properties that have
been proposed to contribute to PD pathogenesis, it is
important to note that the differences between WT, A53T,
A30P, and E46K R-synuclein warn against oversimplifying
the mechanism of neurotoxicity and neglecting the potential
importance of other factors that are not present in our in
Vitro experiments. First, while the A53T and A30P mutations
both promote accumulation of protofibrils in Vitro (10), the
E46K mutation does not, and it in fact reduces the abundance
of such aggregates. Second, the protofibrillar E46K R-sy-
nuclein fraction displays reduced in Vitro permeabilizing
activity in relation to the corresponding WT oligomeric
fraction; A30P and A53T R-synuclein both possess greater
activity than WT in this regard (19). Therefore, if the porelike
activity of R-synuclein is important for neurotoxicity, there
must be factors in the neuronal cytoplasm that reverse the
trends in the intrinsic properties of E46K versus WT
R-synuclein that are observed in Vitro. For example, the target
neuronal membrane will have a different composition than
that of the vesicles optimized for the in Vitro studies
presented here and it is possible that the E46K protofibril
binds to and/or permeabilizes native neuronal membranes
more efficiently than does the WT protofibril. In addition,
many of the properties of the neuronal cytoplasm (local pH,
molecular crowding, calcium concentration, etc.) as well as
cellular regulatory mechanisms (protein modification and
programmed degradation) could affect E46K and WT R-sy-
nuclein differently.
Experiments are underway to correlate in Vitro permeabi-
lizing activity with decreased cellular viability, thereby
addressing the issue of the relevance of the in Vitro
permeabilization assay. While such experiments may also
indicate the strength of the association between R-synuclein
oligomeric species and neuronal degeneration, further puri-
fication of the annular oligomeric form of R-synuclein is
necessary to provide direct evidence of a toxic protofibrillar
pore. Introduction of isolated R-synuclein pores to the
cytoplasm of cultured cells could provide an indication of
the ability of these species to achieve membrane permeabi-
lization under cytoplasmic conditions. These experiments
await the development of a high-resolution separation method
appropriate for R-synuclein aggregates, and may be com-
plicated by the tenuous kinetic stability of the annular species
(16). Ultimately, it is likely that purely biophysical charac-
terization of R-synuclein in isolation will be insufficient to
establish the mechanism or mechanisms by which its
different aggregate forms disrupt cellular homeostasis, as
interactions within the cell may affect the ability of R-sy-
nuclein to self-associate or perform its natural function.
The ability of monomeric R-synuclein to bind to cellular
membranes may be vital to its normal role in the cell, as
evidenced by the fact that A30P R-synuclein (a variant
known to display reduced membrane binding (34, 51)) fails
FIGURE 7: Vesicle permeabilization activity is confined to a specific
subset of soluble oligomeric species of R-synuclein. Shown is an
overlay of chromatograms generated from the eluate from a
Superose 6 SEC column after injection of a WT R-synuclein
preparation enriched in oligomeric species. Protein content (blue
trace) was monitored at 280 nm. Fluorescence increase due to fura-
2-loaded PG vesicle permeabilization (red trace) was monitored at
500 nm (excitation at 334 nm). Note that the fluorescence trace
has been shifted 1 min to the left to account for the volume within
the reaction tubing between the absorbance and fluorescence
detectors. The ordinate has been scaled to best observe the
oligomeric forms of R-synuclein; please note that the peak of
monomeric R-synuclein projects to a relative protein abundance
level of 162.
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to rescue the neurotoxicity associated with the deletion of
the synaptic protein CspR in mice (7). Here we have
demonstrated that monomeric E46K R-synuclein retains the
ability to interact with PG phospholipid vesicles, as illustrated
by the induction of helical character measured by CD. The
proportion of E46K R-synuclein molecules found in a helical
state at any given lipid concentration was highly similar to
that of the WT protein; this indicates that no difference in
binding affinity exists between the variants. This is incon-
sistent with a previous report of elevated affinity of E46K
R-synuclein for synthetic synaptic vesicles (13), and may
reflect the importance of lipid composition in R-synuclein
membrane association. NMR analysis of the E46K variant
in its helical state reveals structural alterations within the
two helical regions of the protein (35, 36) that propagate
well beyond the local site of the mutation. While the
magnitude of these changes is not large enough to suggest
that the secondary structure of the protein is disrupted or
abrogated by the mutation, it is quite likely that the mutation
does result in some rearrangement of the helical structure
with respect to its surrounding environment. Because the two
helices do not contact one another (38, 52, 53), a rearrange-
ment of their relative positions would not be expected to
result in the observed changes. Remaining possible causes
include an alteration in the dynamics of the protein, a
reorientation of the helices with respect to the micelle surface,
or an alteration in the structure and or dynamics of the
micelle itself. In the case of the A30P and A53T mutations
the helical structure of micelle-bound R-synuclein is also
preserved, although the A30P mutation causes a local
perturbation (38, 39). The A30P, but not the A53T, mutation
also led to amide group chemical shift changes that extended
far beyond the site of the mutation. Further study, including
a full-scale structure determination for the E46K mutant
protein and detailed investigations of its interactions with
micelles and lipid membranes, will likely be required to
clarify this issue, but these initial findings indicate that a
subtle structural change in the helical region of E46K is
apparent upon binding to micelles. As the lipid-bound form
of R-synuclein is believed to mediate the normal functions
of the protein, the observation that the E46K mutation has
long-range structural effects in the micelle-bound form of
the protein suggests that this mutation may significantly
influence the normal functions of R-synuclein.
The NMR amide group chemical shift data indicate that
the E46K mutation results in only very minor conformational
changes in the free state of R-synuclein, as might be expected
for a largely unstructured polypeptide. Earlier studies of the
A30P and A53T mutants revealed changes in secondary
structure propensities in the N-terminal lipid-binding domain
of the protein, but these effects were reflected primarily in
carbon chemical shifts (54). More recently several reports
have used paramagnetic relaxation NMR and residual dipolar
constant measurements to document a transient long-range
interaction between a hydrophobic region within the C-
terminal tail of R-synuclein and the N-terminal lipid-binding
domain, which is disrupted by the A30P and A53T mutations
(55-57). This long-range interaction is not associated with
chemical shift changes, and it thus remains possible that a
similar effect is exerted by the E46K mutation. However,
the fact that E46K R-synuclein displays an increase in SEC
retention time in comparison to the WT protein suggests that
such transient interactions may be stabilized by the mutation,
resulting in a more compact conformation. The relationship
between the structure of monomeric R-synuclein while free
in solution and the function (or dysfunction) of the protein
is currently unclear, but the results presented here indicate
that further attention is warranted in this area of study.
The studies detailed above attempt to integrate the proper-
ties of the E46K variant of R-synuclein into the current
understanding of R-synuclein-mediated toxicity through an
examination of its biochemical and biophysical characteris-
FIGURE 8: Both WT and E46K protofibrils permeabilize synthetic vesicles, but WT protofibrils display greater activity. (A) A plot of
integrated peak areas of absorbance (x-axis) and fluorescence (y-axis) taken from Superose 6 chromatograms as shown in Figure 7. WT
protofibrils, filled diamonds; E46K protofibrils, open circles. (B) The average molar activity of protofibrils generated from WT, E46K, and
an equimolar mixture of both. For this analysis, molar activity is defined as the fluorescence peak area divided by the UV peak area for
each point in Figure 8A within the linear portion of each curve. Error bars indicate plus or minus one standard error of 23 replicates (WT),
25 replicates (E46K), and 13 replicates (E46K:WT [1:1]). (**) indicates a p value <0.001 when an unpaired Student’s t test is applied to
the indicated data sets. (C) Average ratio of oligomeric R-synuclein to the monomeric form in the WT and E46K sequence variants. Means
calculated from 7 separate preparations of protofibril-enriched E46K or WT; error bars indicate plus or minus one standard error. (*) p <
0.05.
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tics. The intrinsic properties of oligomeric A53T and A30P
R-synuclein, as measured by vesicle permeabilization and
protofibril accumulation, may be sufficient to model the
accelerated disease progression observed in FPD. It is likely,
however, that extrinsic factors contribute to the toxicity of
R-synuclein in cells, and the results obtained here with E46K
R-synuclein highlight this possibility, as no clear indications
of its increased neurotoxicity are evident in the inherent
properties of the variant in its monomeric and oligomeric
forms. The discovery and evaluation of a third disease-linked
variant of R-synuclein indicates that the current understand-
ing of the molecular mechanism of R-synuclein toxicity in
PD is incomplete, but confirms certain aspects of the toxic
protofibril hypothesis by further supporting the view that
oligomeric R-synuclein is inherently disruptive to mem-
branes. Expanding the scope of analysis in pursuit of a
detailed comprehension of the processing of R-synuclein
within the cell may lead to the identification of specific
therapeutic targets and support the development of drugs to
slow the progression of PD pathology.
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SUPPORTING INFORMATION AVAILABLE
Four figures that illustrate the purity of the protein
employed in the above studies, examine the interaction of
R-synuclein with lipid vesicles, provide structural analysis
of soluble oligomeric fractions of R-synuclein from SEC,
and demonstrate the consistency of the relative rates of fibril
formation between WT and E46K R-synuclein. This material
is available free of charge via the Internet at http://
pubs.acs.org.
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